



**1 November 2024**

## **Appointment of Corporate Advisor**

**Melbourne, Australia, 1 November 2024:** dorsaVi (ASX: DVL) (**dorsaVi** or the **Company**) advises that it has executed a corporate advisory mandate ("Mandate") with 62 Capital Pty Ltd ("62 Capital").

In accordance with the Mandate, 62 Capital will assist the Company in identifying and evaluating potential growth strategies for the Company including but not limited to corporate advisory, mergers and acquisitions, equity and debt raisings and value creating opportunities.

The proposed fees ("Fees") to be paid to the in accordance with the Mandate are performance rights with the following vesting conditions and the issue is subject to shareholder approval:

- (i) 10,000,000 Performance Rights with a vesting condition of DVL achieving, weighted average share price \$0.020 (15-day VWAP, must be achieved within 24 months).
- (ii) 10,000,000 Performance Rights with a vesting condition of DVL achieving, weighted average share price \$0.025 (15-day VWAP, must be achieved within 24 months).
- (iii) 20,000,000 Performance Rights with a vesting condition of DVL achieving, weighted average share price \$0.040 (15-day VWAP, must be achieved within 24 months).

**dorsaVi Chairman Gernot Abl said:**

"On behalf of the dorsaVi Board and management, I am pleased to be working with 62 Capital. 62 Capital have been strong supporters of our Company for a number of years and have a strong foundational understanding of the dorsaVi business and a long-term focus with its portfolio companies. We have confidence this partnership will provide value for the business and support in increasing dorsaVi's reach to access new investor and partner communities"

The release of this announcement was authorised by the Board of dorsaVi.

– ENDS –

**For further information about dorsaVi, please contact:**

**dorsaVi**

Andrew Ronchi  
Chief Executive Officer  
+61 417 882 267  
[ar@dorsavi.com](mailto:ar@dorsavi.com)

**About dorsaVi**

dorsaVi Ltd (ASX: DVL) is an ASX listed company focused on developing innovative motion analysis device technologies for use in clinical applications, elite sports, and occupational health and safety. dorsaVi believes its wearable sensor technology enables, for the first time, many aspects of detailed human movement and position

to be accurately captured, quantified, and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours. dorsaVi's focus is on two major markets:

- **Workplace:** dorsaVi enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to OHS workplace design, equipment or methods based on objective evidence. dorsaVi works either directly with major corporations, or through an insurance company's customer base with the aim of reducing workplace compensation and claims. dorsaVi has been used by major corporations including Sodexo, London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Monash Health, Coles, Woolworths, Toll, Toyota, Orora (formerly Amcor) and BHP Billiton.
- **Clinical:** dorsaVi is transforming the management of patients with its clinical solutions (ViMove, ViMove2 and Professional Suite) which provide objective assessment, monitoring outside the clinic and immediate biofeedback. The clinical market is broken down into physical therapy (physiotherapists), hospital in the home and elite sports. Hospital in the home refers to the remote management of patients by clinicians outside of physical therapy (i.e. for orthopaedic conditions). Elite sports refers to the management and optimisation of athletes through objective evidence for decisions on return to play, measurement of biomechanics and immediate biofeedback to enable peak performance.

Further information is available at [www.dorsavi.com](http://www.dorsavi.com)